Contents

Chapter 1  What is the purpose of this book?  1
Chapter 2  Why is benefit-to-harm balance essential to treatment decisions?  5
Chapter 3  What are the strengths of randomized controlled clinical trials?  11
Chapter 4  What are the weaknesses of randomized controlled clinical trials?  17
Chapter 5  Do meta-analyses provide the ultimate truth?  23
Chapter 6  What are the strengths of observational studies?  29
Chapter 7  What are the weaknesses of observational studies?  35
Chapter 8  Were the scientific questions specified in advance?  39
Chapter 9  Were the treatment groups comparable initially?  45
Chapter 10  Why is blinding/masking so important?  49
Chapter 11  How is symptomatic improvement measured?  53
Chapter 12  Is it really possible to assess quality of life?  57
Chapter 13  What is the value of biologic markers in drug evaluation?  61
Chapter 14  How are adverse drug reactions measured?  67
Chapter 15  How representative are study subjects in clinical trials?  73
Chapter 16  What happened to the study subjects who disappeared from the analysis?  77
Chapter 17  How reliable are active-control trials?  83
Chapter 18  How informative are composite outcomes?  89
Chapter 19  Do changes in biologic markers predict clinical benefit?  95
Chapter 20  How trustworthy are the authors?  99
Chapter 21  Does publication in a reputable scientific journal guarantee quality?  103
Chapter 22  Is it necessary to be a biostatistician to interpret scientific data?  107
Chapter 23  Are all drugs of a class interchangeable?  115
Chapter 24  How much confidence can be placed on economic analysis?  121
Chapter 25  How should I handle the massive flow of information?  125
Chapter 26  How well is research translated into clinical care?  131

Appendix A  Glossary  137
Appendix B  Explanations for checklist questions  143
References  149
Index  159
About the Authors  163
Evaluating Clinical Research
All that glitters is not gold
Furberg, B.D.; Furberg, C.D.
2007, V, 165 p., Softcover
ISBN: 978-0-387-72898-8